Global KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030

List of Tables

Global KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030 Report Findings & Highlights:

Research Methodology
Global & Regional Market Trends Insight
First KRAS Inhibitor Drug Approved In 2021
Global KRAS Market Opportunity To Surpass US$ 2 Billion By 2030
KRAS Inhibitors Market Absolute Growth: >400% Since First Drug Approval
Approved KRAS Inhibitors Drugs: 4 Drugs
Approved Drugs Dosage, Price & Sales Insight
Insight On More Than 80 Drugs In Clinical Trials
KRAS Inhibitor Clinical Trials Insight By Country, Company, Indication & Phase

The global market for KRAS inhibitors has seen substantial growth in recent years, largely due to the heightened awareness of KRAS mutations as significant contributors to cancer development in various solid tumors, including lung, colorectal, and pancreatic cancers. KRAS, an essential gene that regulates cell proliferation, has historically posed a challenge as a therapeutic target because of its intricate biology and its function in supporting tumor survival. Nevertheless, advancements in molecular biology and the creation of targeted therapies have led to the emergence of KRAS inhibitors as a promising category of medications.

A pivotal moment in the KRAS inhibitor market occurred in 2021 with the approval of Lumakras for the treatment of non-small cell lung cancer (NSCLC), representing a significant breakthrough for patients with KRAS G12C mutations. This approval heralded a new phase in targeted cancer therapies, followed by the authorization of Krazati in 2022, and Dupert and Anfangning in 2024 for NSCLC, thereby broadening the treatment landscape for patients with this particular genetic alteration. In 2024 and 2025, the market continued to expand, with both Krazati and Lumakras receiving additional approvals for colorectal cancer (CRC).

At present, more than 80 KRAS inhibitors are in various stages of clinical trials, including Roche's Divarasib, which is currently in Phase 3 trials, and Jacobio Pharma's Glecirasib (JAB-21822), which is undergoing registrational trials in China. The ongoing development of these agents highlights the extensive potential of KRAS inhibitors in addressing a range of malignancies, with numerous clinical trials exploring their use in combination with other cancer treatments, such as chemotherapy, immunotherapy, and targeted therapies. The approval and growing utilization of KRAS inhibitors emphasize their importance in oncology, especially for cancers that have few treatment alternatives and poor outcomes.

Lung cancer, especially non-small cell lung cancer (NSCLC), continues to be the primary focus of research on KRAS inhibitors, with many clinical trials investigating KRAS G12C mutations. Nonetheless, colorectal and pancreatic cancers are also critical areas of study, as KRAS mutations are commonly observed in these types of cancer. The therapeutic potential of KRAS inhibitors extends beyond these malignancies, with ongoing investigations into their effectiveness against other cancers, such as ovarian, brain, and endometrial cancers. Consequently, the global market for KRAS inhibitors is anticipated to broaden, encompassing a wider variety of cancer types, fueled by increasing clinical evidence that supports the efficacy of these treatments across diverse tumor types.

KRAS inhibitors primarily target specific mutations in the KRAS gene, with G12C, G12V, and G12D being the most prevalent. These mutations play a significant role in the oncogenic activation of KRAS, making it an important target for therapeutic strategies. While traditional KRAS inhibitors have focused on either the active or inactive states of the KRAS protein, the emergence of next-generation inhibitors capable of targeting both the "ON" and "OFF" states of KRAS has created new therapeutic possibilities. An example of such an inhibitor is BBO-8520 from BridgeBio Oncology Therapeutics, which covalently binds to both the active and inactive forms of KRAS G12C, effectively preventing effector binding and inhibiting KRAS function. Preclinical studies indicate that BBO-8520 demonstrates greater potency, more profound tumor responses, and a delay in resistance compared to standard KRAS G12C inhibitors, positioning it as a promising option to address the limitations of existing therapies.

Looking ahead, the global market for KRAS inhibitors is set for significant growth as an increasing number of inhibitors advance through clinical trials and receive regulatory approval. Ongoing investigations into combination therapies are expected to broaden the range of treatment options available, targeting various KRAS mutation subtypes and extending to other cancers beyond non-small cell lung cancer (NSCLC). Furthermore, the emergence of more international partnerships and collaborations will likely enhance global access to these vital treatments, thereby benefiting a larger segment of cancer patients. Nevertheless, challenges such as high treatment costs, issues related to accessibility, and the necessity for continued research into long-term efficacy and safety must be addressed to ensure the market's sustainable development.

1. Introduction To KRAS Inhibitors

1.1 Development Of KRAS Inhibitors
1.2 Mechanism Of Action

2. Role Of KRAS Inhibitors In Cancer Therapy

3. Global KRAS Inhibitor Market Outlook

3.1 Current Market Scenario
3.2 KRAS Inhibitors Granted Breakthrough Therapy, Fast Track & Orphan

Designation

3.3 Future Market Opportunity

4. Lumakras - Overview, Pricing, Dosing & Sales Analysis

4.1 Overview & Patent Insight
4.2 Dosage & Price Analysis
4.3 Sales Analysis

5. Krazati - Overview, Pricing, Dosing & Sales Analysis

5.1 Overview & Patent Insight
5.2 Dosage & Price Analysis
5.3 Sales Analysis

6. Dupert - Clinical Insight

7. Anfangning - Clinical Insight

8. KRAS Inhibitor Market Regional Analysis - Commercial & Clinical Development Outlook

8.1 US
8.2 China
8.3 EU
8.4 UK
8.5 Japan
8.6 South Korea
8.7 Canada
8.8 Taiwan
8.9 Australia

9. KRAS Inhibitor Development Trends By Indications

9.1 Lung Cancer
9.2 Colorectal Cancer
9.3 Pancreatic Cancer
9.4 Other Indications

10. Global KRAS Inhibitors Clinical Pipeline Overview

10.1 By Country
10.2 By Phase
10.3 By Company
10.4 By Indication
10.5 By Priority Status

11. Global KRAS Inhibitor Clinical Trials Insight By Country, Company, Indication & Phase

11.1 Research
11.2 Preclinical
11.3 Phase I
11.4 Phase I/II
11.5 Phase II
11.6 Phase III
11.7 Preregistration
11.8 Registered

12. Marketed KRAS Inhibitor Clinical Trials Insight

13. KRAS Inhibitors Combination Strategies

13.1 Immunotherapy
13.2 Chemotherapy
13.3 Targeted Therapies
13.4 Radiation

14. Global KRAS Inhibitors Market Dynamics

14.1 Market Drivers
14.2 Market Challenges

15. Competitive Landscape

15.1 Applied Pharmaceutical Science
15.2 Amgen
15.3 AnBogen Therapeutics
15.4 AstraZeneca
15.5 Biond Biologics
15.6 BridgeBio Oncology Therapeutics
15.7 Bristol Myers Squibb
15.8 Boehringer Ingelheim
15.9 Eli Lilly
15.10 Erasca
15.11 Frontier Medicines
15.12 GenFleet Therapeutics
15.13 Innovent Bio
15.14 Jacobio Pharmaceuticals
15.15 Jiangsu Hansoh Pharmaceutical
15.16 Jiangsu Hengrui Medicine Co.
15.17 Quanta Therapeutics
15.18 Revolution Medicines
15.19 Roche
15.20 Suzhou Zelgen Biopharmaceuticals

List of Figures

Figure 1-1: RAS Mutation - Frequency of KRAS Mutation v/s HRAS & NRAS Mutations
Figure 1-2: KRAS Inhibitors - Development Milestones
Figure 1-3: KRAS Inhibitor - General Mechanism In Cancer
Figure 1-4: KRAS Inhibitors - Targeting Approaches
Figure 1-5: Direct Targeting of Mutant KRAS
Figure 1-6: Targets for Modifying the KRAS Membrane Association
Figure 2-1: KRAS Mutational Frequency By Organ (%)
Figure 2-2: KRAS Inhibitor - Role In Cancer Treatment
Figure 3-1: Approved KRAS Inhibitors
Figure 3-2: Global - KRAS Inhibitors Sales (US$ Million), 2021-2024
Figure 3-3: Global - KRAS Inhibitors Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 3-4: KRAS Inhibitor Market - Future Opportunities
Figure 3-5: Global - KRAS Inhibitors Sales (US$ Million), 2025-2030
Figure 4-1: Sotorasib - Approval Year By Indication
Figure 4-2: Sotorasib - Patent Expiration Year
Figure 4-3: US - Cost Per Unit & Supply Of Lumakras (US$), April'2025
Figure 4-4: EU - Cost Per Unit & Supply Of Lumakras (US$), April'2025
Figure 4-5: Lumakras - Recommended Dose Reduction Levels For Adverse Reaction
Figure 4-6: Global - Lumakras/Lumykras Annual Sales (US$ Million), 2021-2024
Figure 4-7: Global - Lumakras/Lumykras Sales (US$ Million), Q1-Q4'2024
Figure 4-8: Regional - US v/s ROW Lumakras/Lumykras Sales (US$ Million), 2024
Figure 4-9: Regional - US v/s ROW Lumakras/Lumykras Sales (%), 2024
Figure 4-10: US - Lumakras Sales (US$ Million), 2021-2024
Figure 4-11: US - Lumakras Sales (US$ Million), Q1-Q4'2024
Figure 4-12: ROW - Lumakras/Lumykras Sales (US$ Million), 2021-2024
Figure 4-13: ROW - Lumakras/Lumykras Sales (US$ Million), Q1-Q4'2024
Figure 5-1: Krazati - Approval Year By Indication
Figure 5-2: Krazati - Market Exclusivity Expiry By Region
Figure 5-3: US - Cost Per Unit & Supply Of Krazati (US$), April'2025
Figure 5-4: Krazati - Recommended Dosage Reduction for Adverse Reactions (mg/day)
Figure 5-5: Global - Krazati Annual Sales (US$ Million), 2023-2024
Figure 5-6: Global - Krazati Quarterly Sales (US$ Million), Q1-Q4'2024
Figure 5-7: Regional - US v/s ROW Krazati Sales (US$ Million), 2024
Figure 5-8: Regional - US v/s ROW Krazati Sales (%), 2024
Figure 5-9: US - Krazati Sales (US$ Million), Q1-Q4'2024
Figure 5-10: ROW - Krazati Sales (US$ Million), Q1-Q4'2024
Figure 7-1: Garsorasib - NMPA Breakthrough Therapy Designation Year By Indication
Figure 9-1: TBBO8520-101 Phase 1 Study (NCT06343402) - Initiation & Completion Year
Figure 9-2: KRYSTAL-12 Phase 3 Study (NCT04685135) - Initiation & Completion Year
Figure 9-3: RAMP203/VS-6766-203 Phase 1/2 Study (NCT05074810) - Initiation & Completion Year
Figure 9-4: RASolve 301 Phase 3 (NCT06881784) Study - Initiation & Completion Year
Figure 9-5: RMC-LUNG-101 Phase 1/2 (NCT06162221) Study - Initiation & Completion Year
Figure 9-6: CodeBreaK 301 Phase 3 (NCT06252649) Study - Initiation & Completion Year
Figure 9-7: CodeBreaK 101 Phase 3 (NCT04185883) Study - Initiation & Completion Year
Figure 9-8: KRYSTAL-10 Phase 3 (NCT04793958) Study - Initiation & Completion Year
Figure 9-9: RMC-6291-101 Phase 1 (NCT06128551) Study - Initiation & Completion Year
Figure 9-10: RMC-6236-001 Phase 1 (NCT05379985) Study - Initiation & Completion Year
Figure 9-11: RMC-9805-001 Phase 1 (NCT06040541) Study - Initiation & Completion Year
Figure 9-12: BrainMet ADePPT Phase 1 (NCT06807619) Study - Initiation & Completion Year
Figure 9-13: NCI-2023-09685 Phase 1 (NCT06130254) Study - Initiation & Completion Year
Figure 10-1: Global - KRAS Protein Inhibitors Clinical Trials By Country, 2025 -2030
Figure 10-2: Global - KRAS Protein Inhibitors Clinical Trials By Phase, 2025 -2030
Figure 10-3: Global - KRAS Protein Inhibitors Clinical Trials By Company, 2025 -2030
Figure 10-4: Global - KRAS Protein Inhibitors Clinical Trials By Indication, 2025 -2030
Figure 10-5: Global - KRAS Protein Inhibitors Clinical Trials By Priority Status, 2025 -2030
Figure 13-1: KRAS inhibitors & Immunotherapy Combinations
Figure 14-1: KRAS Inhibitors Market - Drivers
Figure 14-2: KRAS Inhibitors Market - Challenges

List of Tables

Table 3-1: KRAS Inhibitors Breakthrough Therapy, Fast Track & Orphan Designation
Table 4-1: Lumakras - Recommended Dosage Modifications For Adverse Reactions
Table 5-1: Krazati - Recommended Dosage Modifications For Adverse Reactions
Table 8-1: US - Ongoing KRAS Inhibitor Clinical Trials
Table 8-2: China - Ongoing KRAS Inhibitor Clinical Trials
Table 8-3: UK - Ongoing KRAS Inhibitor Clinical Trials
Table 8-4: Japan - Ongoing KRAS Inhibitor Clinical Trials
Table 8-5: South Korea - Ongoing KRAS Inhibitor Clinical Trials
Table 8-6: Canada - Ongoing KRAS Inhibitor Clinical Trials
Table 8-7: Taiwan - Ongoing KRAS Inhibitor Clinical Trials
Table 8-8: Australia - Ongoing KRAS Inhibitor Clinical Trials
Table 9-1: Lung Cancer - KRAS Inhibitors In Clinical Trials
Table 9-2: Colorectal Cancer - KRAS Inhibitors In Clinical Trials
Table 9-3: Colorectal Cancer - KRAS Inhibitors With Regulatory Designations
Table 9-4: Pancreatic Cancer - KRAS Inhibitors in Clinical Trials
Table 9-5: Pancreatic Cancer - KRAS Inhibitors with Regulatory Designations
Table 13-1: KRAS Inhibitor & Immunotherapy Combinations In Clinical Trials
Table 13-2: KRAS Inhibitor & Chemotherapy Combinations In Clinical Trials
Table 13-3: KRAS Inhibitor & Targeted Therapy Combinations In Clinical Trials
Table 13-4: KRAS Inhibitor & Radiotherapy Combinations In Clinical Trials

Global KRAS Inhibitors Market, Drug Sales, Patent, Price & Clinical Trials Insight 2030

Description

Table of Contents

List of Tables

Table of Contents

1. Introduction To KRAS Inhibitors

2. Role Of KRAS Inhibitors In Cancer Therapy

3. Global KRAS Inhibitor Market Outlook

4. Lumakras - Overview, Pricing, Dosing & Sales Analysis

5. Krazati - Overview, Pricing, Dosing & Sales Analysis

6. Dupert - Clinical Insight

7. Anfangning - Clinical Insight

8. KRAS Inhibitor Market Regional Analysis - Commercial & Clinical Development Outlook

9. KRAS Inhibitor Development Trends By Indications

10. Global KRAS Inhibitors Clinical Pipeline Overview

11. Global KRAS Inhibitor Clinical Trials Insight By Country, Company, Indication & Phase

12. Marketed KRAS Inhibitor Clinical Trials Insight

13. KRAS Inhibitors Combination Strategies

14. Global KRAS Inhibitors Market Dynamics

15. Competitive Landscape

List of Figures

List of Tables